Generic Evista, Raloxifene Tablet Articles
Various Side Effects of Evista Raloxifene and Its Warnings
Title: Various Side Effects of Evista Raloxifene & Its Warnings
Most postmenopausal women from all over the world rely upon generic Evista (Raloxifene) to get rid of their osteoporosis or bone loss problem. This oral drug works in an effective way to retard bone loss, to make bones solid, and to lower the danger of fractures or ruptures. However, it may cause a number of potential side effects in users as usually happened with any medication.
Taking generic Evista may lead to Evista Raloxifene: Drug Usage, Precautions & Interactions to Consider
Osteoporosis or bone loss is quite prevalent among postmenopausal women. Continuous bone erosion will significantly increase the risk of fractures among women. To treat and prevent bone loss, there are a number of effective prescription and generic drugs available both online and offline. Generic Evista (Raloxifene) is one such potent drug used by women to treat osteoporosis after menopause. The drug slows down the process of bone loss, thereby sustaining strong bones and warding off fr Use Evista Raloxifene to Treat Osteoporosis & Cancer Simultaneously
Raloxifene manufactured by Eli Lily and Company under the trade name Evista is a multi-faceted drug. As a selective estrogen receptor modulator (SERM), it performs both estrogenic activities and anti-estrogenic activities on bone, and on the breast and uterus respectively. Its estrogenic actions on bone prevents osteoporosis or abnormal loss of bony tissue in postmenopausal women.
As per an announcement made on April 17, 2006, Evista (Raloxifene) was labeled on equal terms with tamoxifen in d EVISTA
Evista [raloxifene hydrochloride] is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.
EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, and for reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.
|
